ChyloCure is an innovative player in the Biotechnology and Health Care sectors, founded in 2020. The company primarily focuses on its flagship product, Chylobinoid, a premium cannabinoid formulation. This product distinguishes itself by offering a composition of 70% CBDa, supplemented with approximately 5% cannabidiol (CBD), 5% other cannabinoids, 4% magnesium, and naturally occurring plant lipids.
The Chylobinoid formula is designed to ensure safe, effective, and consistent dosing, setting it apart from traditional medicinal cannabinoids by promoting several health benefits. Despite the lack of a specified headquarters, ChyloCure attracts attention for its unique product development approach that capitalizes on the demand for advanced cannabinoid products.
The company last secured a $150.00K debt financing investment on 25 January 2021, though specific investors remain unnamed. Investors might find potential in ChyloCure's novel product offerings within a growing industry.
